Uta Griesenbach, Professor of Molecular Medicine, National Heart and Lung Institute Imperial College London

Uta is a Professor of Molecular Medicine and has over 25 years experience in developing advanced therapeutics. Her research interests are related to the development of gene therapy for cystic fibrosis (CF) and other lung diseases. She has overseen vector and biomarker development, toxicology studies, as well as vector manufacturing and has been a Co-I on several clinical trials. Uta is a member of the UK Respiratory Gene Therapy Consortium (GTC) strategy group, Co-director of the Imperial Centre for Excellence in Advanced Therapies, a Co-founder of AlveoGene (Imperial College Spinout) and a Non-executive director of the Cell and Gene Therapy Catapult. In addition to her research activities, she has an active role in education and workforce development related to advanced therapeutics in the UK.

Steven Howe, Resolution Therapeutics

Steven has more than 25 years of experience working in cell and gene therapy, including postdoctoral positions at the UCL Great Ormond Street Institute of Child Health, London, before joining GlaxoSmithKline in 2015 as Senior Director of Product Development leading a team in developing manufacturing processes for advanced therapies.

During his career Steven has led groups researching a wide range of advanced therapies and technologies to apply them, including viral vectorology, stem cell biology and cell processing. His recent positions have focused on Process Development for manufacturing platforms to translate cell and gene therapies into the clinic, for disease areas including rare diseases, metabolic disorders and cancer.

In his current role at Resolution Therapeutics, he leads the team responsible for developing manufacturing approaches to produce regenerative macrophage therapies to treat inflammatory and fibrotic disease.